{
    "brief_title": "Testosterone & Tamoxifen Trial",
    "phase": "",
    "drugs": "['AndroGel']",
    "drugs_list": [
        "AndroGel"
    ],
    "diseases": "['Male Breast Cancer']",
    "diseases_list": [
        "Male Breast Cancer"
    ],
    "enrollment": "6.0",
    "inclusion_criteria": "inclusion criteria: \n\n Male \n\n A history of proven ER+ (>10% of cells), AR+ (>10% of cells), and HER2- metastatic BC \n\n Tumor progression after at least one line of conventional endocrine therapy (tamoxifen, AI, fulvestrant, CDK4/6, \u00b1LHRH analogue). \n\n Age \u2265 18 years \n\n Adequate hematological, renal and liver function as follows: \n\n Absolute neutrophil count > 1.5 x 109/L \n\n Platelet count >100 x 109/L \n\n White blood cell count >3 x 109/L \n\n AST and ALT <2.5 or <5.0 in case of liver metastases x upper limit of normal (ULN) \n\n Creatinine clearance >50mL/min \n\n Prothrombin time, partial thromboplastin time and INR <1.5 x ULN \n\n Written informed consent \n\n ",
    "exclusion_criteria": ": \n\n History of prostate, testicular or liver cancer \n\n Patients already using testosterone supplements \n\n Patients using medication with anti-androgenic effects (e.g. spironolactone) \n\n Elevated PSA (>4\u03bcg/L) or severe urinary tract problems (as defined with a Prostate Symptom Score >19). Patients with known BRCA mutation and PSA >3 \u03bcg/L will be referred to the urologist for prostate cancer screening, and can participate if they have no signs of prostate cancer. \n\n Hematocrit >50% \n\n Patients with uncontrolled hypertension, diabetes mellitus or other significant cardiovascular morbidity. \n\n Patients with recent history of coronary artery disease or trombo-embolic events within 6 months prior to screening \n\n Severe concurrent disease, infection, co morbid condition that, in the judgment of the investigator would make the patient inappropriate for enrollment \n\n Visceral crisis and/or rapid progression necessitating chemotherapy \n\n Previous allergic reaction to androgen agonists \n\n Contra-indication for PET imaging \n\n Tamoxifen or fulvestrant treatment <5 weeks prior to FES-PET.",
    "brief_summary": "This is a concise single arm, feasibility study, which will be executed in the University Medical Center Groningen, The Netherlands. Male patients with metastatic BC (n=6) are eligible for this study after at least 1 line of conventional endocrine therapy.",
    "NCT_ID": "NCT05156606"
}